Business Wire

NTT-DOCOMO/NEC

26.2.2024 09:06:25 CET | Business Wire | Press release

Share
DOCOMO and NEC to Establish “OREX SAI” Joint Venture to Provide OREX Packages for Open RAN Global Deployments

NTT DOCOMO, INC. and NEC Corporation announced today that they plan to establish a joint venture company, OREX SAI, INC. on April 1 to provide OREX Packages solutions for the full-scale global deployment of Open RAN services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226531069/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Overview of OREX SAI (Graphic: Business Wire)

OREX SAI will locally source products and services from members of OREX PARTNERS in each market and perform system verifications to deliver mobile networks tailored to the needs of each overseas telecommunications operator. Leveraging NEC’s established business infrastructure and global network in over 50 countries and territories, the joint venture will accelerate its global expansion of Open RAN business.

In addition, DOCOMO and NEC plan to strengthen cooperation with OREX PARTNERS through OREX SAI to promote the commercialization and realization of true Open RAN that enables the interoperability of equipment and systems from diverse vendors.

The joint venture will procure all necessary Open RAN network equipment and software from OREX PARTNERS, and then conduct system verification for the planning and construction of optimal mobile networks tailored to each telecom operator. Full-stack services will include planning, construction, maintenance and operation under the OREX Packages framework.

DOCOMO established the O-RAN ALLIANCE with leading global telecom operators in February 2018 and launched the world’s first nationwide Open RAN 5G service in Japan in March 2020. Since introducing the OREX® brand in February 2023, DOCOMO has been supporting Open RAN verifications for global telecom operators to help realize more open mobile networks around the world.

NEC, having delivered Open RAN solutions to telecom operators in Japan and other countries, was selected by DOCOMO as a vendor for virtualized radio access networks (vRANs), one of DOCOMO’s 5G commercial services in Japan. With extensive experience in building communication infrastructure around the world, NEC offers strong system-integration (SI) capabilities.

In their collaboration with OREX PARTNERS to realize Open RAN, DOCOMO and NEC recognize the importance of optimizing local product and service delivery. In response, they will now form a joint venture company to establish a global system capable of accelerating the realization of Open RAN.

Hiroshi Kobayashi, President and CEO of OREX SAI, said, “We are excited to bring our true Open RAN solutions to telecom operators worldwide through the joint venture OREX SAI, which combines DOCOMO’s Open RAN implementation expertise, OREX’s innovative solutions and NEC’s global system-integration capabilities. We are committed to driving innovation and connectivity for all, making global telecommunications open, seamless and inclusive.”

Going forward, OREX SAI will work with OREX PARTNERS to provide optimal products and services that accelerate the global adoption of high-quality, cost-effective and energy-efficient Open RAN solutions. In addition, they will enhance cooperation with global partners to foster a vibrant and open ecosystem.

The new company will also explore application of the NTT’s IOWN all-photonic network for transmission, the use of low-power servers equipped with optoelectronic devices, and collaboration with the Cognitive Foundation®.

Joint Venture Overview

Official Name

OREX SAI, INC.

Headquarters

59-16 Nisshin-cho,

Kawasaki-ku, Kawasaki City,

Kanagawa, Japan 210-0024

President and CEO

Hiroshi Kobayashi

Business

  • Sales of Open RAN equipment and services
  • Open RAN construction, maintenance, and operation
  • Planning of SMO, vRAN, and other initiatives

Total Assets

JPY 16 billion (including capital reserve)

Establishment

April 1, 2024 (tentative)

Shareholders

DOCOMO 66% and NEC 34%

OREX is a trademark of NTT DOCOMO, INC.

For more detailed information, please refer to the full press release available at www.docomo.ne.jp/english/info/media_center/pr/

About NTT DOCOMO

NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226531069/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye